2024-10-22T14:55:21-05:00 2024-06-30 593040705 RIVERO GORDIMER & COMPANY PA 201 N FRANKLIN ST SUITE 2200 TAMPA FL 33602 990 2023-07-01 593097333 NATIONAL PEDIATRIC CANCER FOUNDATION INC NATI 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 20 TAMPA FL 33609 DAVID FRAZER CHIEF EXECUTIVE OFFICER 8132690955 2024-10-22 1 1 SAM A LAZZARA P01342929 8138757774 2023 2024-10-15 13:58:12Z DAVID FRAZER 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 6919788 0 X WWW.NATIONALPCF.ORG X 1991 FL THE NPCF IS DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. 23 23 27 300 0 0 4618153 4516155 0 0 128799 161711 102571 332222 4849523 5010088 2905436 2820170 0 0 1349742 1589140 0 0 315650 695897 665731 4951075 5075041 -101552 -64953 6837500 7031609 1023962 930873 5813538 6100736 X NATIONAL PEDIATRIC CANCER FOUNDATION (NPCF) IS A NONPROFIT ORGANIZATION DEDICATED TO FUNDING RESEARCH TO ELIMINATE CHILDHOOD CANCER. OUR FOCUS IS TO FUND RESEARCH TO FIND LESS TOXIC, MORE TARGETED THERAPIES BY PARTNERING WITH LEADING HOSPITALS NATIONWIDE. 0 0 4494421 2820170 THE NATIONAL PEDIATRIC CANCER FOUNDATION FUNDS PEDIATRIC CANCER RESEARCH WITH THE GOAL OF LEADING TO THE TREATMENT AND ELIMINATION OF PEDIATRIC CANCER WORLDWIDE.WE ACCOMPLISH OUR MISSION THROUGH OUR RESEARCH INITIATIVE, THE SUNSHINE PROJECT, AN INNOVATIVE COLLABORATION OF 30 HOSPITALS NATIONWIDE. THIS COLLABORATIVE RESEARCH MODEL IS UNIQUE AND EFFECTIVE IN ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS AGAINST CHILDHOOD CANCER.SEE SCHEDULE O FOR FURTHER PROGRAM SERVICE ACCOMPLISHMENTS.IN DEVELOPING THIS COLLABORATION, THE FOUNDATION HAS BROUGHT TOGETHER SOME OF THE COUNTRY'S LEADING INVESTIGATORS AND INSTITUTIONS TO DRIVE THE PROCESS OF FINDING A CURE. INVESTIGATORS ARE PERFORMING THREE VITAL PHASES OF RESEARCH SIMULTANEOUSLY: BASIC SCIENCE, TRANSLATIONAL RESEARCH AND CLINICAL TRIALS. THESE MAJOR RESEARCH COMPONENTS NOT ONLY ALLOW DOCTORS TO IDENTIFY NEW AGENTS IN FIGHTING CANCER, BUT ALSO HELP RESEARCHERS TO UNDERSTAND THE CANCER CELLS RESPONSE TO THE DRUG. THE NATIONAL PEDIATRIC CANCER FOUNDATION IS MAKING GREAT STRIDES IN ITS MISSION TO FIND A CURE FOR CHILDHOOD CANCER.CURRENT INITIATIVES OF THE SUNSHINE PROJECT ARE AS FOLLOWS:SARCOMA TRIALS (OSTEOSARCOMA, RHABDOMYOSARCOMA, EWING SARCOMA, NON-RHABDOMYOSARCOMA)1. PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR TREATMENT OF RECURRENT/REFRACTORY SARCOMA IN TEENAGERS AND YOUNG ADULTS - THIS TRIAL WILL LOOK AT THIS COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE IN ITS ABILITY TO PREVENT THE FORMATION OR GROWTH OF TUMORS IN TEENAGERS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA, EWING SARCOMA, RHABDOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMA. THE TRIAL WILL ALSO LOOK AT THE LENGTH OF TIME DURING AND AFTER TREATMENT THAT THE DISEASE DOES NOT GET WORSE, AND DETERMINE IF NAB-PACLITAXEL COMBINED WITH GEMCITABINE IS SAFE AND TOLERABLE.2. A PHASE IB/II STUDY TO EVALUATE THE SAFETY, FEASIBILITY AND EFFICACY OF NIVOLUMAB OR NIVOLUMAB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA - THIS WILL BE THE FIRST TIME BOTH DRUGS, NIVOLUMAB AND AZACITIDINE ARE BEING USED IN COMBINATION TO TREAT OSTEOSARCOMA. HIS TRIAL WILL DETERMINE IF THE COMBINATION OF AZACITIDINE AND NIVOLUMAB CAN IMPROVE EVENT FREE SURVIVAL OVER THE 20% HISTORICAL CONTROL USED FOR RECURRENT OSTEOSARCOMA STUDIES IN THE CHILDREN'S ONCOLOGY GROUP.3. EVOLUTIONARY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA - METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA (RMS) HAVE A POOR OUTCOME WHICH IS WORSENED WITH ADDITIONAL RISK FACTORS COMMONLY CALLED THE OBERLIN CRITERIA. PATIENTS THAT MEET ALL 4 OBERLIN CRITERIA HAVE AN EVENT FREE SURVIVAL (EFS) OF LESS THAN 20% AT 2 YEARS. ALL THERAPEUTIC ARMS ON THIS STUDY ARE DESIGNED TO MEET THE SAME PRIMARY AIM OF IMPROVING THE 3 YEAR EVENT FREE SURVIVAL FROM 6% TO 35% FOR THESE PATIENTS. 4. ACTION TRIAL: ADOPTIVE CELLULAR THERAPY FOLLOWING DOSE-INTENSIFIED TEMOZOLOMIDE IN NEWLY-DIAGNOSED PEDIATRIC HIGH-GRADE GLIOMAS (PHASE I) - THIS IMMUNOTHERAPY TRIAL WILL EXPLORE THE SAFETY OF ADOPTIVE CELLULAR THERAPY IN PEDIATRIC PATIENTS WITH HIGH GRADE GLIOMAS (HGG) WHO HAS RECEIVED DOSE INTENSIFIED TEMOZOLOMIDE AND DENDTRIC CELL (DC) + AUTOLOGOUS LYMPHOCYTE TRANSFER (XALT) WITH AND WITHOUT AUTOLOGOUS HEMATOPOETIC STEM CELLS (HSCS). WE WILL ALSO BE EXAMINING FEASIBILITY OF ALL ENROLLED PATIENTS COMPLETING TREATMENT AND ANALYZING PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL AFTER THIS TREATMENT. 5. BLOOD BASED BIOMARKERS FOR MINIMAL RESIDUAL DISEASE DETECTION IN PEDIATRIC SARCOMAS - THE PURPOSE OF THIS STUDY IS TO SEE IF DETECTING CELL-FREE PLASMA TUMOR DNA (PTDNA) AND CIRCULATING TUMOR CELLS (CTC) CAN PREDICT RECURRENCE OF DISEASE IN PATIENTS WHO ARE IN RADIOGRAPHIC REMISSION 2-3 WEEKS AFTER TREATMENT. PLASMA TUMOR DNA (PTDNA) IS FREE FLOATING DNA FROM THE TUMOR FOUND IN THE BLOOD STREAM AND CIRCULATING TUMOR CELLS.6. A MULTI-INSTITUTION STUDY OF TGF? IMPRINTED, EX VIVO EXPANDED UNIVERSAL DONOR NK CELL INFUSIONS AS ADOPTIVE IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC BONE AND SOFT TISSUE SARCOMAS: THE TINKS TRIAL - THE PURPOSE OF THIS TRIAL IS TO DETERMINE THE SAFETY OF THE ADDITION OF ADOPTIVE TRANSFER OF UNIVERSAL DONOR, TGFB IMPRINTED (TGFBI), EXPANDED NK CELLS TO GEMCITABINE/DOCETAXEL (GEM/DOX) FOR TREATMENT OF RELAPSED AND REFRACTORY SARCOMAS AND TO DETERMINE THE 6 MONTH PROGRESSION FREE SURVIVAL ACHIEVED WTIH THIS TREATMENT.7. FEASIBILITY OF GENERATING NOVEL TRANSLATIONAL AND THERAPEUTIC STRATEGIES BASED ON A MULTICENTER, PEDIATRIC AND AYA EVOLUTIONARY TUMOR BOARD (PEDSETB) - PEDIATRIC EVOLUTIONARY TUMOR BOARD (PEDSETB) IS A MULTIDISCIPLINARY FORUM TO APPROACH AN INDIVIDUAL PATIENT'S CANCER AND PROPOSE ADDITIONAL IDEAS FOR CARE. THE PEDSETB WILL GATHER TOGETHER DISCIPLINES NOT OFTEN ENGAGED IN CANCER WORK AND USE INSIGHTS FROM EVOLUTION TO OPTIMALLY MODEL, RESEARCH, AND IMPACT PEDIATRIC CANCER OUTCOMES. STRATEGIES FROM PEDSETB'S PREDECESSOR HAVE BEEN INSTRUMENTAL IN THE DESIGN OF SEVERAL OF NPCF'S MOST RECENT CLINICAL TRIALS8. EVALUATION OF DIGOXIN FOR RELAPSED NON-WNT, NON-SHH MEDULLOBLASTOMA (PHASE 2 STUDY) - THIS TRIAL WILL EVALUATE THE EFFICACY OF DIGOXIN IN TREATING PATIENTS WITH RELAPSED NON-SHH, NON-WNT MEDULLOBLASTOMA AND TO DETERIMINE IF DIGOXIN IMPROVES PROGRESSION FREE SURVIVIAL AT 4 MONTHS AFTER INITATION OF STUDY TREATMENT IN THIS PATIENT POPULATION. 9. METASTATIC EWING'S TRIAL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES - THIS TRIAL WILL TEST OUR ABILITY TO ADMINISTER FREQUENTLY CHANGING CHEMOTHERAPY REGIMENS, CALLED SEQUENTIAL SECOND STRIKES, TO PATIENTS WITH WIDELY METASTATIC EWING SARCOMA TO STOP ITS DEVELOPMENT OF RESISTANCE TO CHEMOTHERAPY AND IMPROVE CURE RATES.SUNSHINE PROJECT LABORATORY THE SUNSHINE LAB CONTINUES WITH THE IMPORTANT TASK OF FINDING PROMISINGNEW TREATMENT REGIMENS FOR SARCOMAS, AMONG THE MOST DEADLY PEDIATRIC CANCER. DURING THIS PAST YEAR, THE SUNSHINE LAB HAS BUILT ON COMBINATION DRUG SCREENING PLATFORM AND FOCUSED ON OSTEOSARCOMA AND EWING SARCOMA.PEDIATRIC SARCOMAS OFTEN SHRINK OR GO AWAY WITH INITIAL THERAPY BUT THEN LATER RELAPSE AND ARE THEN MUCH MORE DIFFICULT TO CURE. THIS SUGGESTS THAT A SMALL AMOUNT OF DISEASE ELUDES CURRENT THERAPY. WE CONSIDER THIS SMALL, RESISTANT POPULATION SHOULD BE THE FOCUS OF PRECLINICAL RESEARCH AND HAVE 3 MAJOR PROJECTS RESULTING FROM THAT UNDERSTANDING OF PEDIATRIC SARCOMA. 1. WE HAVE DEVELOPED A MODEL OF THESE TWO COMPETING POPULATIONS,TERMED HETEROGENEITY, TO FIGURE OUT THE BEST STRATEGY TO ELIMINATE BOTH CANCER CELL POPULATIONS WITH TIMING AND COMBINATIONS OF THERAPIES. 2. IN COLLABORATION, WE ARE INVESTIGATING "SECOND STRIKES" IN BOTH OSTEOSARCOMA AND EWING SARCOMA. SECOND STRIKES ARE THERAPIES AFTER THE DISEASE HAS SHRUNK WITH INITIAL THERAPY. RATHER THAN SHRINK THE TUMOR,WE ARE INVESTIGATING THERAPIES TO ELIMINATE THE RESIDUAL CELLS BETTER THAN CONTINUING THE INITIAL THERAPY (FIRST STRIKE). THIS RESULTED FROM THE SUNSHINE LAB PARTICIPATING IN THE 9TH ANNUAL INTEGRATED MATHEMATICAL ONCOLOGY WORKSHOP AT MOFFITT CANCER CENTER. 3. IN COLLABORATION, WE HAVE FOCUSED ON A NEW, NON-MUTATED TARGET IN OSTEOSARCOMA, THE CMG HELICASE. WE HAVE BOTH IDENTIFIED THIS AS A WEAKNESS IN CANCER CELLS MORE THAN NORMAL CELLS AND IDENTIFIED A DRUG CLASS THAT HOLDS PROMISE AS AN EVENTUAL THERAPY. WE ARE EXPLORING THIS AGENT ALONE AND IN COMBINATION TO MAXIMIZE THE CHANCE FOR A SUCCESSFUL CLINICAL TRIAL. 4. IN COLLABORATION, WE ARE BUILDING ON PRIOR PUBLICATIONS SHOW ACTIVITY OF EPIGENETIC DRUGS LIKE PANOBINOSTAT AND EXPLORING MECHANISMS TO ENHANCE THIS THERAPY IN OSTEOSARCOMA. 5. IN COLLABORATION, WE ARE INVESTIGATING AN UNDERAPPRECIATED DNA REPAIR ENZYME AS AN ACHILLES HEEL IN EWING SARCOMA CALLED PARP16. 4494421 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 119 0 1 27 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 23 23 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 FL AL AK CA CO CT DC GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI X X X NATIONAL PEDIATRIC CANCER FOUNDATION INC 8132690955 5550 WEST EXECUTIVE DRIVE SUITE 200 TAMPA FL 33609 MICHAEL LEVIN CHAIRMAN OF THE BOARD 2.00 X X 0 0 0 CHAD HARROD VICE CHAIRMAN 2.00 X X 0 0 0 ALBERT SILVA VICE CHAIRMAN 2.00 X X 0 0 0 JEREMY PERSINGER TREASURER 2.00 X X 0 0 0 JIM BASSIL SECRETARY 2.00 X X 0 0 0 MELISSA DUNKEL AT LARGE DIRECTOR - EMERITUS 1.00 X 0 0 0 FRANK CAPITANO AT LARGE DIRECTOR 1.00 X 0 0 0 JEFF MAXWELL AT LARGE DIRECTOR 1.00 X 0 0 0 JOSEPH LAMPHIER DIRECTOR - EMERITUS 1.00 X 0 0 0 MARCO SCHNABL DIRECTOR 1.00 X 0 0 0 MARK MCHUGH DIRECTOR 1.00 X 0 0 0 RICHARD HUFF DIRECTOR 1.00 X 0 0 0 BB ABBOTT DIRECTOR 1.00 X 0 0 0 CARRIE CHARLES DIRECTOR 1.00 X 0 0 0 DAN DOYLE JR DIRECTOR 1.00 X 0 0 0 JOHN FITZPATRICK DIRECTOR 1.00 X 0 0 0 PHILIP MINARDI DIRECTOR 1.00 X 0 0 0 ANGELA NORTH DIRECTOR 1.00 X 0 0 0 DAWN SILER-NIXON DIRECTOR 1.00 X 0 0 0 MIKE WEIGNER DIRECTOR 1.00 X 0 0 0 ALEX SULLIVAN DIRECTOR 1.00 X 0 0 0 CHRIS CARRERE DIRECTOR 1.00 X 0 0 0 DAVID BOYINGTON DIRECTOR 1.00 X 0 0 0 DAVID FRAZER CEO 40.00 X 206262 0 0 DAWN ZACHMAN COO 40.00 X 113385 0 0 ROBERT MARTIN CFO 40.00 X 144810 0 0 464457 0 0 3 0 1 0 0 629613 3886542 5682 4516155 161711 161711 2234858 629613 1909700 325158 325158 MISCELLANEOUS REVNEUE 900099 7064 7064 7064 5010088 0 0 493933 2806572 2806572 13598 13598 464457 399599 42333 22525 973068 837186 88691 47191 42209 36315 3847 2047 109406 94128 9972 5306 29395 14292 15103 24465 24465 30398 30398 8737 8737 117313 5307 7946 104060 18947 12371 3445 3131 98419 81477 11819 5123 44120 36957 4533 2630 27140 2125 2207 22808 11197 1000 45 10152 38580 34047 2777 1756 46995 41517 3357 2121 31363 24589 5217 1557 ONLINE TRANSACTION FEES 49588 3121 46467 POSTAGE AND SHIPPING 42141 19502 564 22075 CONTRACT LABOR 37758 31888 4290 1580 LICENSES AND PERMITS 3535 299 3236 5640 1951 541 3148 5075041 4494421 264970 315650 809161 1273888 60273 32475 123012 193136 1642349 131656 1522783 1510693 4076098 3750447 246173 270970 6837500 7031609 107769 76027 38800 189597 877393 647870 0 17379 1023962 930873 X 5503653 5418356 309885 682380 5813538 6100736 6837500 7031609 -64953 352151 0 X X 0 1 X 1 0 X 3247093 4078949 3578042 3041195 3886542 17831821 3247093 4078949 3578042 3041195 3886542 17831821 1719970 16111851 61466 958567 99773 128799 161711 1410316 19242137 3063481 0.83730 0.87170 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 2097998 28104 221424 2347526 1904761 30479 162758 2097998 2194890 25172 -315301 1904761 1013600 883542 297748 2194890 923363 100000 -9763 1013600 0.89000 0.03000 0.08000 0 0 1545000 78580 1466420 97349 53076 44273 1510693 FINANCING LEASE PAYABLE 17379 17379 X 5335715 352151 3874 356025 4979690 30398 30398 5010088 5048517 3874 3874 5044643 30398 30398 5075041 PART X, LINE 2: THE FOUNDATION HAS RECEIVED A DETERMINATION OF TAX EXEMPT STATUS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES IS REFLECTED IN THE ACCOMPANYING FINANCIAL STATEMENTS. MANAGEMENT IS NOT AWARE OF ANY ACTIVITIES THAT WOULD JEOPARDIZE THE FOUNDATION'S TAX EXEMPT STATUS. THE FOUNDATION IS NOT AWARE OF ANY TAX POSITIONS IT HAS TAKEN THAT ARE SUBJECT TO A SIGNIFICANT DEGREE OF UNCERTAINTY. TAX YEARS AFTER JUNE 30, 2020 REMAIN SUBJECT TO EXAMINATION BY TAXING AUTHORITIES. PART V, LINE 4: THE NATIONAL PEDIATRIC CANCER FOUNDATION MAINTAINS AN ENDOWMENT FUND AT THE COMMUNITY FOUNDATION OF TAMPA BAY, INC. FOR THE LONG TERM BENEFIT OF THE NATIONAL PEDIATRIC CANCER FOUNDATION. FASHION FUNDS THE CURE 1727396 351758 1375638 35000 1079984 FISHING FUNDS THE CURE 644474 27249 617225 4350 534632 8 492601 250606 241995 16675 239059 2864471 629613 2234858 56025 1853675 1909700 325158 1 H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501(C)(3) 100104 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 603918 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 820000 0 FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL CHILDREN'S HOSPITAL OF COLORADO FOUNDATION 13123 E 16TH AVE AURORA CO 80045 840813462 501(C)(3) 126526 0 BIOMARKER TRIAL PILLAR PROJECT CONDUCTED UNDER THE SUNSHINE PROJECT UNIVERSITY OF FLORIDA PO BOX 115500 GAINESVILLE FL 32611 596002052 501(C)(3) 50000 0 IN SUPPORT OF CLINICAL TRIAL ADVANCING INKT STUDY CONNECTICUT CHILDREN'S MEDICAL CENTER 282 WASHINGTON ST HARTFORD CT 06106 222619869 501(C)(3) 52971 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 21210 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. VANDERBILT UNIVERSITY MEDICAL CENTER 3319 WEST END AVE SUITE 700 NASHVILLE TN 37203 352528741 501(C)(3) 12037 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE UNIVERSITY OF NORTH CARLINA AT CHAPEL HILL 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NC 27599 566001393 501(C)(3) 56763 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL PO BOX 781653 DETROIT MI 48278 311036372 501(C)(3) 160154 0 IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. PARATOPE BIO INC 1013 CENTRE RD SUITE 403-A WILMINGTON DE 19805 920860458 300000 0 FOR 43 CHALLENGE PROJECT - HARNESSING THE POWER OF INNATE ANTIBODIES FOR NOVEL THERAPIES IN PEDIATRIC CANCER RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 10889 WILSHIRE BLVD SUITE 700 LOS ANGELES CA 90095 943067788 501(C)(3) 400000 0 FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY JOHN HOPKINS UNIVERSITY 1800 ORLEANS STREET BLOOMBERG 11N BALTIMORE MD 21287 520595110 501(C)(3) 50000 0 IN SUPPORT OF CLINICAL TRIAL ADVANCING RHABDOMYOSARCOMA RESEARCH CHILDREN'S RESEARCH INSTITUTE 1 INVENTA PLACE WEST TOWER 3RD FLOOR SILVER SPRING MD 20910 521640402 501(C)(3) 52889 0 IN SUPORT OF INKT TRIAL CONDUCTED UNDER THE SUNSHINE PROJECT 13 1 SAFETY NET GRANT FOR REIMBURSABLE MEDICAL EXPENSES NOT COVERED BY INSURANCE 15 13598 FMV X X 0 0 0 0 0 0 0 0 0 DAVID FRAZER CEO 187680 0 18582 0 0 0 0 0 0 0 206262 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS RECEIVES THE DRAFT OF THE FORM 990 AND APPROVES THE FORM 990 PRIOR TO THE FORM BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION'S CONFLICT OF INTEREST POLICY IS DISCUSSED AT ORIENTATION OF OFFICERS AND DIRECTORS ON A PERIODIC BASIS, AT LEAST ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE CEO AND OTHER KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE EXECUTIVE COMMITTEE AND BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 THE NATIONAL PEDIATRIC CANCER FOUNDATION MAKES ITS GOVERNING DOCUMENTS, PRIVACY POLICY AND FINANCIAL INFORMATION AVAILABLE FOR PUBLIC INSPECTION THROUGH THE ORGANIZATION'S WEBSITE AS WELL AS UPON REQUEST. FORM 990, PART XII, LINE 2C, FINANCIAL STATEMENTS AND REPORTING THE PROCESS FOR OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT HAS NOT CHANGED FROM THE PRIOR YEAR.